NICE has given the green light for lung cancer drug Keytruda to be used as a routine treatment for certain patients in England. Merck, Sharp, and Dohme (MSD)’s Keytruda (pembrolizumab) will be ...

MSD’s immunotherapy Keytruda (pembrolizumab) has gained a NICE recommendation for NHS England routine commissioning for the first-line treatment of non-small cell lung cancer (NSCLC). NICE has ...

NICE has said MSD’s cancer immunotherapy, Keytruda, should receive interim funding on the NHS in certain patients with untreated lung cancer, in combination with chemotherapy. In first draft guidance, ...

RAHWAY, N.J. - Merck, known as MSD outside the United States and Canada, announced the European Commission's approval of KEYTRUDA, its anti-PD-1 therapy, for a new lung cancer treatment regimen. This ...

Merck & Co., Inc. MRK announced data from a phase III study which showed that treatment with its PD-1 inhibitor, Keytruda monotherapy led to significantly improved overall survival (OS) as a ...

RAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC ...

Collaboration seeks to advance the treatment of non-small cell lung cancer by combining Keytruda with Moderna’s novel neoantigen therapy, which has shown positive results across cancer types. Merck ...

Patients with lung cancer are to be barred from routine NHS access to MSD's immunotherapy Keytruda in England and Wales after cost regulators concluded that it could not be considered a cost-effective ...

Merck & Co., Inc.’s MRK PD-L1 inhibitor, Keytruda ruled at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago as the drug giant presented additional data from two ...

RAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency ...

Benzinga - by Vandana Singh, Benzinga Editor. Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from hase 3 KEYNOTE-522 trial of Keytruda in high-risk early-stage triple-negative breast cancer ...